
Top scientists flag little-known earliest signs of dementia that have nothing to do with memory
Dementia, a condition which blights the lives of millions, famously causes problems with patients' memory, language and mood.
Medics, using tools like memory tests and interviews, assess these when diagnosing the condition.
But now scientists say there is substantial evidence that dementia starts to impair the senses many years before a patient shows the classic signs.
This they say, offers hope that sensory changes can be used as an early warning sign and help patients be diagnosed far sooner.
They have now called for such changes to be included in standard dementia diagnostic tests which have predominantly focused on recording memory difficulties.
An early diagnosis for dementia is considered critical as, while the condition is incurable, treatments can combat symptoms and sometimes slow progression.
The team includes three dementia experts in Professor Andrea Tales, of Swansea University, Dr Emma Richards of Public Health Wales and Professor Jan Kremláček of Charles University in Prague.
'Broadening the diagnostic approach beyond memory testing raised the potential to identify dementia at preclinical stages when therapies and life modifications may be most effective,' Professor Kremláček explained.
Dr Richards added: 'Many patients report experiencing these sensory changes years before receiving a diagnosis, but these symptoms may be overlooked during standard cognitive assessments.
'Understanding and addressing these issues, and providing support earlier could be transformative, enabling health care providers to offer the vital emotional and social support patients need at a potentially confusing and distressing time.
'In addition to this, understanding changes in a person's senses can help support a clinician in determining a dementia diagnosis.'
Dementia, and particularly early signs of the condition, has been linked to changes in sensory perception before.
As the condition is neurodegenerative, meaning it causes continuous brain atrophy, loss of brain tissue and volume, over time, this is believed to have an impact on how our senses function, even in the early stages.
Earlier this year neurologists highlighted that a loss of sense of smell could be an early sign of dementia and strike 10-years before better-known symptoms.
It isn't just smell—vision disturbances and problems with balance are some of the earliest, but often dismissed, signs, especially in younger patients.
Writing for The Conversation earlier this year, Molly Murray, an expert in young-onset dementia from the University of West Scotland, said for many patients the first sign of the condition is a problem with their eyes.
'Research shows that for around one third of people with young-onset Alzheimer's disease [the most common form of dementia] , the earliest symptoms they had were problems with coordination and vision changes,' she wrote.
Experts have also warned that problems with spatial awareness such as standing too close to people are also potential dementia warning signs which can occur up to twenty years before the classic symptoms.
More than 944,000 people in the UK are thought to be living with dementia, while the figure is thought to be around seven million in the US.
Recent analysis by the Alzheimer's Society estimated the overall annual cost of the dementia to the UK is £42billion a year, with families bearing the brunt.
An ageing population means these costs—which include lost earnings of unpaid carers—are set to soar to £90billion in the next 15 years.
A separate Alzheimer's Research UK analysis found 74,261 people died from dementia in 2022 compared with 69,178 a year earlier, making it the country's biggest killer.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


BBC News
39 minutes ago
- BBC News
Adult day centres in Powys to close with families left disappointed
Day centres in parts of Powys will close after the council confirmed plans to reorganise services for adults with additional day centres in Llanidloes, Ystradgynlais and Brecon, which all offer services to adults with disabilities or learning difficulties from 18 will shut. The centres are described by families as a "necessary resource" that eases the burden on council said services will be provided in different ways, "either through supported living providers or from other venues". Taylor Johnson, 20, has been attending Sylfaen Day Centre in Llanidloes for two years. Her mum Nicola Barrett said "it's important to her". "They want to make it more community based but there's nowhere for people like Taylor," she said. "I don't know what the future holds for her really in being able to access the community and seeing her peers."She's just going to be plunged back into isolation with me again and that's going to have an effect on her mental health and her understanding of why she's stuck at home with me."The council is finding new ways of providing services, which are currently provided through a mixture of statutory services and support from the third sector, with the aim of saving £277,000. The day centres are a paid service, with families describing low numbers as an essential part of the one-to-one care that many users Davies' brother Gareth, 36, also attends the day centre and describes the decision as "morally wrong"."Gareth has autism and any routine change really disrupts him. Mental health is supposed to be protected and Gareth looks forward to it," he said."He goes there to see his friends - it's the highlight of his week."Powys council said that the reorganisation of services will see the creation of five hubs in Welshpool, Newtown, Llandrindod Wells, Brecon and Ystradgynlais - with an outreach service provided from the hubs to their surrounding Cabinet Member for a Caring Powys Sian Cox said the new model "will deliver increased capacity in key areas and provide a more flexible and sustainable approach to supporting people to meet the outcomes that are important to them".


Daily Mail
3 hours ago
- Daily Mail
We took part in America's largest ever study on how to beat dementia. These simple lifestyle changes de-aged our brains
Phyllis Jones spent nearly 10 years watching her mother succumb to Alzheimer's. Decades earlier, her mother had taken care of her grandmother the same way, as she was also struck by the most common form of memory-robbing dementia. Your browser does not support iframes. Your browser does not support iframes.


The Independent
7 hours ago
- The Independent
Warning issued to patients after using weight-loss jabs
Health chiefs have raised concerns about patients regaining weight after stopping popular weight-loss drugs such as Wegovy and Mounjaro, calling for robust support to prevent them from piling on the pounds again. The National Institute for Health and Care Excellence (Nice), the UK's health watchdog, highlighted research indicating that many individuals regain weight if not adequately supported after ceasing treatment. Nice stressed that those coming off the drugs should be offered "structured advice and follow-up support" to mitigate weight gain. This guidance specifically applies to individuals receiving these treatments through the NHS. However, an estimated 1.5 million people in the UK are currently using weight-loss injections, with the vast majority paying privately. These individuals will not be eligible for NHS support once their treatment concludes. Over the next three years, approximately 240,000 people deemed to have the "greatest need" are anticipated to receive Mounjaro, also known as tirzepatide, via the NHS. The new 'quality standard' from Nice says that NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme,' said Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice. 'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made. 'This new standard makes sure services provide that vital continuity of care, and it supports the NHS 10 Year Plan to shift from a 'sickness service' to a genuine health service focused on prevention.' Dr Rebecca Payne, chair of Nice's Quality Standards Advisory Committee, added: 'Weight management is a long-term journey, not a short-term fix. 'The evidence is clear that advice and support for maintaining weight after stopping medicines or completing behavioural interventions can help prevent weight regain and enable people to experience lasting benefits. 'We've seen excellent examples of services that already provide comprehensive discharge planning and ongoing support. 'This quality standard will help ensure all healthcare providers adopt these best practices, giving every person the best chance of maintaining their weight management success over the long term. 'This standard ensures healthcare services are equipped to provide that essential ongoing support.' Commenting, Henry Gregg, chief executive of the National Pharmacy Association, said: ' Pharmacies take their responsibilities seriously to provide full wrap around support to patients trying to achieve a healthy weight. 'We know that although medication can be effective in speeding up weight loss in some people, it is not a silver bullet and patients need to make long term lifestyle changes to make their weight loss sustainable. 'The current NHS roll out of weight loss treatment is very small, with only a handful of patients receiving it and it will continue to be the case that the vast majority of eligible patients will be seen by their pharmacy.' Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'There is no one-size-fits-all approach to tackling obesity – what works for one patient will likely not work for another and, as with any medication, weight-loss drugs do not come without risk. 'It's also the case that patients will likely need support to sustain their weight loss once they stop taking the medication. As such, this is important and sensible guidance from Nice. 'As a college, we've been clear that whilst weight loss medications have significant potential benefits for patients who are struggling to lose weight, they mustn't be seen as a 'silver bullet' and ensuring access to sufficient 'wraparound' services – particularly for when patients come off their medication – will be key to optimal health outcomes.'